Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul;13(3):391-5.
doi: 10.2450/2014.0184-14. Epub 2014 Nov 25.

Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: a meta-analysis of randomised controlled trials

Affiliations
Review

Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: a meta-analysis of randomised controlled trials

Matteo N D Di Minno et al. Blood Transfus. 2015 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Forest plot of the primary efficacy outcome (recurrent VTE or VTE-related death) for DOAC vs VKA in patients with unprovoked (Panel A) or provoked (Panel B) VTE. DOAC: direct oral anticoagulant; VKA: Vitamin K antagonist; M-H: Mantel-Haenszel effect; CI: confidence interval.

References

    1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I4–8. - PubMed
    1. Coppola A, Tufano A, Cerbone AM, et al. Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost. 2009;35:683–94. - PubMed
    1. White RH. Identifying risk factors for venous thromboembolism. Circulation. 2012;125:2051–3. - PubMed
    1. Di Minno MN, Tufano A, Guida A, et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res. 2011;127:193–7. - PubMed
    1. Baglin T, RL, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors. Lancet. 2003;362:523–6. - PubMed

MeSH terms